Technology for Healthier Ingestion of Drugs

Lexaria Bioscience Corp. acquired the precursor to the DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an u …

Lexaria Bioscience DehydraTECH High Tide cannabis accessories

Lexaria Bioscience has partnered with a world-leading tobacco company to license their technology.

Lexaria Bioscience Corp. acquired the precursor to the DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria has emerged as a global leader in enhancing the speed of action, flavor and gastro-intestinal delivery of orally-administered products.

The Lexaria family of companies has also demonstrated early-stage effectiveness in improvements of delivery through human skin for the potential development of topically-administered products, including patches, cremes and lotions.

In 2018, Lexaria created four different wholly-owned subsidiary companies to each focus on commercial opportunities in their respective industries: Nicotine; Pharmaceuticals; Hemp; and Other. Together, they are empowered with global exclusive licenses to utilize and sub-license DehydraTECH worldwide for the delivery of molecules within their respective industries.

Lexaria has conducted ground-breaking studies to open doors previously closed to disruptive new delivery technology, including the possibility of potent and fast acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking. And, because of the demonstrated improvements in delivery, DehydraTECH also opens the possibility of utilizing micro doses in accordance with evolving FDA policies related to reducing delivered quantities of substances like nicotine.

In 2018, Lexaria demonstrated in animal studies a propensity for the DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain-barrier, initiating additional new patent applications.

Lexaria produces industry-leading research to support its novel delivery methods. Lexaria’s business model depends on industry partners who license its technology for additional R&D and consumer product development.

For more information on Lexaria Biosciences Corp. (LXX:CSE, LXRP:OTCQX) please fill out the form below.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info